文献速递重症综合管理与镇静镇痛心脑血管急症

静脉-动脉体外膜氧合期间的神经系统并发症及其对6个月以患者为中心结局的影响

Neurologic Complications During Venoarterial Extracorporeal Membrane Oxygenation and Their Implications for 6-Month Patient-Centered Outcomes.
PubMed 文献 · Crit Care Med · 2025-11-10
一句话结论静脉-动脉ECMO期间发生神经系统并发症者6个月死亡或新发残疾风险增加17.28%,主要由死亡风险增加驱动。

该前瞻性多中心观察性研究纳入澳大利亚和新西兰30家ECMO中心2019年2月至2022年12月收治的704例非体外心肺复苏适应证的成人静脉-动脉ECMO患者,按是否发生神经系统并发症分组,主要终点为6个月死亡或新发残疾复合终点。613例(86.2%)有主要终点数据,其中425例(69.3%)达到主要终点。神经系统事件发生于85例(12%),与死亡或新发残疾风险增加相关(风险差17.28%[6.44-25.92%]),主要归因于死亡风险增加(风险差23.75[12.06-34.75]),而非新发残疾(风险差-11.90%[-30.58%至13.56%])。作者认为应优先预防这些并发症并开发更好的功能结局预后工具。

要点

  • 静脉-动脉ECMO成人患者中神经系统并发症发生率为12%(85/704),包括弥漫性脑缺血、卒中、脑出血和脑死亡。
  • 发生神经系统并发症者6个月死亡或新发残疾风险差为17.28%(95%CI 6.44-25.92%),主要来自死亡风险增加(风险差23.75,95%CI 12.06-34.75)。
  • 新发残疾风险差为-11.90%(95%CI -30.58%至13.56%),未达统计学显著。
  • 发生神经系统并发症者更常因判断预后不良而终止ECMO(OR 2.7,95%CI 1.35-24.7)。
  • 作者认为应优先预防神经系统并发症并开发更好的功能结局预后工具。

适用人群与场景

  • 澳大利亚和新西兰30家ECMO中心2019年2月至2022年12月收治的成人静脉-动脉ECMO患者,排除体外心肺复苏适应证者。
  • 纳入704例,中位年龄54.5岁(42-64岁),女性259例(36.8%)。

研究设计与关键结果

  • 前瞻性、多中心、观察性研究,30家ECMO中心,704例成人静脉-动脉ECMO(非体外心肺复苏)患者,按是否发生神经系统并发症分组。
  • 神经系统并发症包括弥漫性脑缺血、卒中、脑出血和脑死亡,发生于85例(12%)。
  • 主要终点6个月死亡或新发残疾:613例(86.2%)有数据,425例(69.3%)达到主要终点。
  • 发生神经系统并发症者死亡或新发残疾风险增加:风险差17.28%(95%CI 6.44-25.92%)。
  • 死亡风险差23.75(95%CI 12.06-34.75),新发残疾风险差-11.90%(95%CI -30.58%至13.56%)。
  • 因判断预后不良而终止ECMO:OR 2.7(95%CI 1.35-24.7)。
  • 次要结局包括世界卫生组织残疾评定量表和EuroQoL 5D五水平量表测量的生活质量和残疾。

证据类型、等级与局限

  • 证据类型:前瞻性、多中心、观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为应优先预防静脉-动脉ECMO期间的神经系统并发症,并开发更好的功能结局预后工具。
  • 原文未据此给出其他推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Venoarterial extracorporeal membrane oxygenation (ECMO) is associated with neurologic complications but their impact on long-term outcomes are poorly understood. Our objective was to assess the association of neurologic complications with death and new disability at 6 months.

DESIGN: Prospective, multicenter, observational study.

SETTING: Thirty ECMO centers in Australia and New Zealand between February 2019 and December 2022.

SUBJECTS: seven hundred four adult patients admitted to the ICU on venoarterial ECMO other than for extracorporeal cardiopulmonary resuscitation.

INTERVENTIONS: None.

MEASUREMENT AND MAIN RESULTS: Patients were divided according to whether they experienced neurologic complications. Neurologic complications include diffuse cerebral ischemia, stroke, cerebral hemorrhage, and brain death. The primary outcome was a composite of death or new disability at 6 months. Secondary outcomes included disability measured by the World Health Organization Disability Assessment Schedule and quality of life measured with EuroQoL 5D five levels. The median age of patients was 54.5 years (42-64 yr) and 259 (36.8%) were female. The primary outcome was available for 613 of 706 patients (86.2%). Of these, 425 patients (69.3%) had either died or had new disability at 6 months. Neurologic events occurred in 85 patients (12%). Patients who experienced neurologic complications were at increased risk of death or new disability (risk difference [RD], 17.28% [6.44-25.92%]). This was primarily due to an increased risk of mortality RD, 23.75 (12.06-34.75) rather than new disability (RD, -11.90% [-30.58% to 13.56%]). These findings were consistent across types of complications and after adjustment for confounders. Patients with neurologic complications more commonly had ECMO discontinued due to a perceived poor prognosis (odds ratio, 2.7; 95% CI, 1.35-24.7).

CONCLUSIONS: Neurologic complications during ECMO increased the risk of death and disability at 6 months, primarily driven by increased death at 6 months. Prevention of these complications and development of better prognostic tools for functional outcomes should be prioritized.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Brown A, Dennis M, Rattan N, et al. Neurologic Complications During Venoarterial Extracorporeal Membrane Oxygenation and Their Implications for 6-Month Patient-Centered Outcomes. Crit Care Med. 2025. PMID: 41212045. doi:10.1097/CCM.0000000000006938

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。